Neurocrine Biosciences Inc. completed the acquisition of Soleno Therapeutics Inc. on May 18, 2026, after successfully tendering approximately 88.9% of Soleno's shares at $53.00 each, totaling around $2.9 billion.
AI Assistant
NEUROCRINE BIOSCIENCES INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.